Thalidomide in multiple myeloma
- PMID: 11204667
Thalidomide in multiple myeloma
Abstract
Recent evidence suggests that angiogenesis is increased in multiple myeloma and has prognostic value in the disease. Based on the increased angiogenesis observed in myeloma, thalidomide (Thalomid) has been studied as antiangiogenic therapy. Although its mechanism of action in myeloma is unclear, several trials show that thalidomide is active in 25% to 35% of patients with relapsed myeloma. Since many patients who respond have failed other active regimens, including transplantation, these results are impressive. Major toxicities include constipation, sedation, skin rash, fatigue, and peripheral neuropathy. Studies are ongoing to determine its role as initial treatment for myeloma. Trials are also underway combining thalidomide with other active agents. This article summarizes the current status of thalidomide therapy in myeloma.
Similar articles
-
Current status of thalidomide in the treatment of cancer.Oncology (Williston Park). 2001 Jul;15(7):867-74; discussion 877-9. Oncology (Williston Park). 2001. PMID: 11499688 Review.
-
A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.Cancer Treat Rev. 2000 Oct;26(5):351-62. doi: 10.1053/ctrv.2000.0188. Cancer Treat Rev. 2000. PMID: 11006136 Review.
-
Thalidomide in the treatment of multiple myeloma.Expert Rev Anticancer Ther. 2001 Jun;1(1):20-8. doi: 10.1586/14737140.1.1.20. Expert Rev Anticancer Ther. 2001. PMID: 12113124 Review.
-
Thalidomide: present and future in multiple myeloma.Expert Rev Anticancer Ther. 2005 Feb;5(1):25-31. doi: 10.1586/14737140.5.1.25. Expert Rev Anticancer Ther. 2005. PMID: 15757435 Review.
-
Thalidomide in the treatment of relapsed multiple myeloma.Mayo Clin Proc. 2000 Sep;75(9):897-901. doi: 10.4065/75.9.897. Mayo Clin Proc. 2000. PMID: 10994824
Cited by
-
Repurposing bioactive compounds for treating multidrug-resistant pathogens.J Med Microbiol. 2020 Jun;69(6):881-894. doi: 10.1099/jmm.0.001172. J Med Microbiol. 2020. PMID: 32163353 Free PMC article.
-
Drug Repurposing Approaches towards Defeating Multidrug-Resistant Gram-Negative Pathogens: Novel Polymyxin/Non-Antibiotic Combinations.Pathogens. 2022 Nov 25;11(12):1420. doi: 10.3390/pathogens11121420. Pathogens. 2022. PMID: 36558754 Free PMC article. Review.
-
Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma.Med Oncol. 2002;19(4):219-26. doi: 10.1385/MO:19:4:219. Med Oncol. 2002. PMID: 12512915
-
Antagonistic effect of small-molecule inhibitors of Wnt/β-catenin in multiple myeloma.Anticancer Res. 2012 Nov;32(11):4697-707. Anticancer Res. 2012. PMID: 23155232 Free PMC article.
-
Efficacy and safety of thalidomide in patients with β-thalassemia intermedia and major.Medicine (Baltimore). 2024 Oct 25;103(43):e40328. doi: 10.1097/MD.0000000000040328. Medicine (Baltimore). 2024. PMID: 39470504 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
